Endpoint
Seizure frequency 50% responder rate
CAT:outcome/seizure-frequency-50-percent-responder-ratereported in proportion2 findings from 1 compound
What moved it
How to read these marks2 findings · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| cannabidiol | up | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
2 findings
cannabidiol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The meta‐analysis results for the logistic regression on the 50% responder rate, the key secondary endpoint, also favored CBD vs. placebo regardless of CLB co‐therapy.”
Quoted verbatim from Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 55 years with Lennox-Gastaut syndrome or Dravet syndrome in four pooled phase 3 trials; CBD 10 and 20 mg/kg/day versus placebo, both CBD doses combined, analysed in strata with and without concomitant clobazam; antiseizure drugs continued in both arms
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.2020PMID:32592183Industry fundedPermalink
cannabidiol — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“In the overall DS population, CBD resulted in a greater reduction in convulsive seizures (0.71 [0.60‐0.83], p < 0.0001) and higher ≥50% responder rates (2.34 [1.51‐3.63], p = 0.0001) compared with placebo.”
Quoted verbatim from Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 18 years with Dravet syndrome in two pooled phase 3 trials (GWPCARE1B and GWPCARE2), all CBD doses (10 and 20 mg/kg/day) versus placebo, overall population; concomitant antiepileptic drugs in both arms
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.2021PMID:32969022Industry fundedPermalink
How it is measured
Proportion of epilepsy patients whose seizure frequency, counted from a seizure diary over a stated baseline period and a stated treatment period, falls by at least 50% from baseline. The seizure type counted and the length of the baseline and treatment periods are recorded with each finding.
Sources cited
2 papers
- Subject
- seizure frequency 50% responder rate
- Findings
- 2
- Papers
- 2